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Abstract
Background: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant tumor
susceptibility syndrome, and the disease-related gene has been identified as fumarate hydratase (fumarase, FH).
HLRCC-associated kidney cancer is an aggressive tumor characterized by early metastasis to regional lymph nodes
and distant organs. Since early diagnosis and provision of definitive therapy is thought to be the best way to reduce
the tumor burden, it is widely accepted that germline testing and active surveillance for an at-risk individual from a
family with HLRCC is very important. However, it still remains controversial how we should treat HLRCC-associated
kidney cancer. We successfully treated the patient with locally advanced HLRCC-associated kidney cancer, who has
received active surveillance because of at-risk individual, by radical nephrectomy and extended retroperitoneal lymph
node dissection, and examined surgically resected samples from a molecular point of view.
Case presentation: We recommended that 13 at-risk individuals from a family with HLRCC should receive active
surveillance for early detection of renal cancer. A 48-year-old woman with a left renal tumor and involvement of
multiple regional lymph nodes with high accumulation of fluorine-18-deoxyglucose on positron emission tomography
was treated with axitinib as a neoadjuvant therapy. Preoperative axitinib induced the shrinkage of the tumor with
decreased fluorine-18-deoxyglucose accumulation. Resected samples showed two thirds tumor tissue necrosis as well
as high expression of serine/threonine kinase Akt and low expression of nuclear factor E2-related factor 2 (Nrf2) which
activates anti-oxidant response and protects against oxidative stress in viable cancer cells. Targeted next-generation
sequencing revealed that FH mutation and loss of the second allele were completely identical between blood and
tumor samples, suggesting that FH mutation plays a direct role in FH-deficient RCC. She has remained well after radical
operation for over 33 months.
Conclusions: FH mutation plays a role in tumorigenic feature, a metabolic shift to aerobic glycolysis, and increased an
anti-oxidant response phenotype in HLRCC-associated kidney cancer.
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Background
Hereditary leiomyomatosis and renal cell cancer (HLRCC,
Online Mendelian Inheritance in Man accession number
605839) is a recently identified autosomal dominant
tumor susceptibility syndrome that is characterized by a
predisposition to develop benign leiomyomas of the skin
and the uterus (fibroids and myomas), as well as aggres-
sive renal cell cancer with papillary type 2 (pRCC2) or
collecting duct histology [1–3]. The disease-related gene
has been identified as fumarate hydratase (fumarase, FH,
Online Mendelian Inheritance in Man accession number
136850) located at 1q43. FH encodes an enzyme that is
part of the mitochondrial tricarboxylic acid (TCA) cycle
involved in cellular energy metabolism and appears to
function as a tumor suppressor since its activity is very
low or absent in tumors from individuals with HLRCC.
HLRCC-associated kidney cancer has distinctive architec-
tural and morphologic features, is particularly aggressive,
and tends to metastasize to regional lymph nodes and
distant organs early [4]. Therefore, a high detection rate
of mutations in HLRCC families may enable early iden-
tification of at-risk individuals and allow early initiation
of therapy while their tumors are still small. However,
it stills remains controversial how we should treat
HLRCC-associated kidney cancer [5]. So far, there have
been several case reports regarding HLRCC-associated
kidney cancer, however, most of those were reporting
the mutation analysis of FH, pathological features, and
clinical course. Furthermore, to our knowledge, there
have been no case reports of the patients of at-risk of
HLRCC-associated with kidney cancer who received active
surveillance and were treated successfully, and little is
known about the relationship between the clinicopathologi-
cal features and molecular changes associated with
targeting therapy in this disease. In the present study,
we successfully treated a patient with locally advanced
HLRCC-associated pRCC2 by neoadjuvant administration
of axitinib and subsequent radical nephrectomy and
extended retroperitoneal lymph node dissection.
FH-deficient RCC is characterized by enhanced aerobic
glycolysis and increased anti-oxidant response phenotype
[6, 7]. Overactivation of phosphatidylinositol 3‘kinase
(PI3K), serine/threonine protein kinase B (Akt), and
mammalian target of rapamycin (mTOR) pathway has
been reported in RCC. Inhibition of Akt disrupts tran-
scription of glucose transporter protein-1 (GLUT1) and
its translocation to the plasma membrane to promote
glucose utilization independent of an effect on cell pro-
liferation [8]. Phosphorylation at two sites is required
for full activation of Akt, since it is phosphorylated by
PI3K-dependent kinase-1 (PDK1) at a threonine residue
in the catalytic domain (Thr-308) and by PI3K-dependent
kinase-2 (PDK2) at a serine residue (Ser-473) in the
carboxy-terminal hydrophobic motif [9]. mTOR has dual
rapamycin-sensitive (mTOR-raptor complex: mTORC1) and
rapamycin-insensitive (mTOR-rictor complex: mTORC2)
functions. mTORC1 is activated by PI3K-Akt and it
phosphorylates S6 and eukaryotic translation initiation fac-
tor 4E-binding protein 1 (4EBP1), thereby promoting
translation and protein synthesis. mTORC2 regulates the
actin cytoskeleton and also possesses PDK2 activity that
phosphorylates Ser-473 at the carboxy-terminus of Akt,
which is essential for activation of Akt [10, 11], and
mTORC2-pAkt(Ser-473) signaling affects energy metab-
olism and cell survival [12]. Activation of Akt may in-
crease cell viability after inhibition of mTORC1 [9].
Hypoxia-inducible factor (HIF)1α expression is dependent
on both raptor and rictor, whereas HIF2α expression only
depends on rictor, with HIF2α and mTORC2 being more
important in RCC [13]. Moreover, phosphorylation of
Ser-473 in Akt is considered to be key molecular step in
the progression of RCCs and could be a potential target
[10, 11, 14]. Furthermore, available reports support HIF-
dependent pseudo-hypoxia manner as the mechanism of
tumorigenesis in HLRCC [15]. In FH-deficient kidney
cancer cells, increased fumarate inactivate prolyl hydroxy-
lases, leading to stabilization of HIF, and increased HIF
target genes such as GLUT1, vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF), and transforming growth factor (TGF)α, which
facilitate tumor growth [7, 16].
On the other hand, HIF-independent manner has
been recently reported [17]. FH-deficiency leads to
succination of Kelch-like ECH-associated protein 1
(Keap1), stabilization of nuclear factor E2-related fac-
tor 2 (Nrf2), and induction of stress-response genes
including HMOX1, which is important for the survival
of FH-deficient cells. The Keap1-Nrf2 pathway is the
major regulator of cytoprotective responses to oxida-
tive and electrophilic stress. Although cell signaling
pathways triggered by the transcription factor Nrf2
prevent cancer initiation and progression in normal
and premalignant tissues, in fully malignant cells Nrf2
activity provides growth advantage by increasing
cancer chemoresistance and enhancing tumor cell
growth, and high Nrf2 protein level is associated with
poor prognosis in cancer [18]. FH loss results in Keap1
inactivation and Nrf2-dependent activation of anti-oxidant
pathways [19, 20].
Axitinib is a potent, selective, second-generation
inhibitor of VEGF receptor (VEGFR) 1, 2, and 3 that
blocks VEGFRs at sub-nanomolar drug concentrations
[21], and relative potency of axitinib is 50–450 times
greater than that of the first-generation VEGFR inhibitors
like sorafenib or sunitinib [22]. In order to investigate the
roles of Akt-mTOR pathway and Nrf2 anti-oxidant
response element transcription pathway in HLRCC-
associated kidney cancer, we examined the expressions
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of phosphorylated-Akt (Ser-473) (pAkt(Ser-473), phosphor-
ylated-Akt (Thr-308) (pAkt(Thr-308), phosphorylated-S6
ribosomal protein (Ser-235/236) (pS6), and Nrf2 in surgi-
cally resected samples. We also investigated FH mutations
by sequencing the coding exons and intron flanking
regions in both blood and tumor samples by targeted
next-generation sequencing analysis. Such information
might be useful to understand the signaling pathway in
HLRCC-associated kidney cancer from a molecular point
of view.
Case presentation
A 48-year-old woman (III-8, a sister of the proband from
this HLRCC family) underwent abdominal ultrasonog-
raphy annually at a local clinic after 2007, and presented
with a left renal mass detected by an ultrasonography and
was introduced to our hospital in March 2013 (Additional
file 2: Figure S1).
She had undergone enucleation myomectomy for uterine
leiomyomatosis at the age of 29 years at another hospital,
while hysterectomy had been performed for recurrence
large uterine leiomyomatosis at the age of 39 years at other
hospital. In 2007 (when she was 40), her sister was
diagnosed with HLRCC having a novel FH mutation at
241,671,938 bp (C574T) by direct sequencing of the FH
gene from leukocyte DNA. Her sister subsequently died
of HLRC-associated advanced renal cancer. In 2007,
sequencing of DNA extracted from blood cells of this
patient confirmed that she also had the same FH mutation
as her sister [23]. After 2007, we recommended that 13
members of this family with the FH mutation should
receive active surveillance by annual imaging (abdominal
plain computed tomography (CT) or ultrasonography) at
a convenient clinic (Fig. 1).
Laboratory tests revealed moderate anemia (hemoglobin:
9.3 g/dl) and elevation of serum C-reactive protein (CRP:
3.19, normal < 0.3 mg/dl). Karnofsky performance status
(KPS) was 100 %. Plain CT scans obtained at our hospital
showed a left renal tumor with a diameter of 7 cm and
involvement of multiple regional para-aortic lymph
nodes, but no distant metastases (cT3aN1M0) (Fig. 2a).
Positron emission tomography (PET) showed fluorine-
18-deoxyglucose (FDG) accumulation in the renal tumor
and the metastatic lymph node and the maximum
Fig. 1 Pedigree. Generations are represented by Roman numerals and individuals are shown by Arabic numerals. The present patient is III-8
(indicated by the arrow) and the proband is III-9. “Mut” shows mutation screening. “Mut +” and “Mut −” indicate mutation-positive and
mutation-negative individuals, respectively
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standardized uptake value (SUVmax) was 15.3 and 7.5,
respectively (Figs. 2b,c).
Her risk classification for renal cancer was intermediate
risk according to the Memorial Sloan-Kettering Cancer
Center (MSKCC) criteria. However, the prognosis of pa-
tients with HLRCC-associated renal cancer, in particular
those with extrarenal involvement, is extremely poor.
Furthermore, her tumors showed a different imaging
pattern from that of typical clear cell RCC (Additional
file 2: Figure S1), and the histology of the renal cancers
in her relatives was non-clear cell RCC (undifferentiated
RCC in her mother, pRCC2 in both her sister and mater-
nal cousin). Thus, the tumor of this patient seemed likely
to be non-clear cell carcinoma, but we did not perform
needle biopsy to avoid dissemination of cancer cells.
In order to decrease the tumor burden and improve
the feasibility of surgery, we selected preoperative treatment
with a multi-targeted tyrosine kinase inhibitor (TKI). In
comparison to first-generation TKIs targeting the VEGFR,
axitinib is a potent second-generation inhibitor of VEGFRs
with a higher affinity for tyrosine kinase and achieves
stronger inhibition of kinase activity with fewer adverse
effects such as thrombocytopenia. Additionally, first-
generation inhibitors block other targets, such as PDGF
receptors (PDGFR), KIT (cluster of differentiation 117:
CD117), b-rapidly accelerated fibrosarcoma (RAF), and
Fms-like tyrosine kinase 3 (FLT-3), which are not substan-
tially inhibited by axitinib. These off-target activities might
contribute to the adverse effects of the first-generation
inhibitors, suggesting that more specific inhibitors of
VEGFR such as axitinib might have an enhanced thera-
peutic window. We recently successfully treated a pa-
tient who had a large right RCC showing sarcomatoid
differentiation that directly invaded the duodenum and
inferior vena cava with regional lymph node involvement.
In this patient, radical right nephrectomy, cavotomy
with thrombectomy, and pancreatoduodenectomy were
successfully performed after administration of axitinib as
first-line neoadjuvant therapy without severe toxicity [24].
We selected axitinib as preoperative molecular-targeting
therapy to decrease the tumor size before surgery with
good tolerability. Administration of axitinib starting at
5 mg/day was scheduled for four to six weeks before rad-
ical surgery involving left nephrectomy and extended
retroperitoneal lymph node dissection (para-aortic and
aorto-caval nodes). After 1 week, the dose of axitinib was
Fig. 2 Positron emission tomography (PET) with [18 F] fluorodeoxyglucose (18 F-FDG PET) / plain computed tomography (CT). Pre: Before
treatment with axitinib. Post: After administration of axitinib for 4 weeks. a, d: Plain abdominal CT shows that the primary left renal tumor and
enlarged lymph nodes have decreased in size. b, e: SUVmax of the primary tumor decreased from 15.3 to 2.9 after administration of axitinib.
c, f: SUVmax of the regional lymph nodes decreased from 7.5 to 2.3 after administration of axitinib
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increased to 14 mg/day. After four weeks of total dose of
axitinib of 329 mg (5 mg/day for continuous 7 days and
14 mg/day for following continuous 21 days), there
were no apparent adverse events of > grade 3, excluding
headache and hypertension (systolic blood pressure >
200 mmHg). Tumor shrinkage and a decrease of SUVmax
were observed (Figs. 2d-f). Subsequently, we successfully
carried out radical left nephrectomy and extended retro-
peritoneal lymph node dissection (para-aortic and aorto-
caval nodes). Macroscopically, the tumor was an invasive
whitish-yellowish mass with partial necrosis. Pathological
examination confirmed pRCC2 with Fuhrman grade 3
differentiation (pT3apN1M0). The pathological effect
of axitinib was grade 2 (i.e., two-thirds necrosis of the
tumor). The patient has been receiving axitinib at 5 mg/day
in the manner of one cycle of one week (5 days on - 2 days
off ) as adjuvant therapy for 33 months, and remains
well with no evidence of recurrence at 33 months after
the operation.
Materials and methods
Western blotting and Immunohistochemistry
We performed Western blotting using a rabbit anti-human
antibody targeting pAkt (Ser-473) (Cell Signaling Technol-
ogy, Inc; PhosphoPlus Akt (Ser-473) Antibody Kit; # 9270,
Danvers, MA), a rabbit anti-human antibody for pAkt
(Thr-308) (Cell Signaling Technology, Inc; Phospho-Akt
(Thr308) Antibody Kit; # 2965, Danvers, MA), a rabbit
anti-human antibody targeting phosphorylated ribosomal
protein S6 kinase (pS6) (2 F9, Cell Signaling Technology,
Inc; # 4856), as described previously [25].
Immunohistochemical staining was performed with
anti-Nrf2 monoclonal antibody (abcam, # ab-62352,
Cambrige, UK) using the immunoperoxidase technique
and microwave treatment of tissue sections in citrate
buffer as described previously [26].
For comparison to the present case, we examined the
expression of pAkt (Ser-473), pAkt (Thr-308) and pS6 in
surgical specimens of five patients with locally advanced
clear cell RCCs with pT3bpN1 or pT4 who received
preoperative axitinib as well as the current patient, and
of Nrf2 in HLRCC-associated kidney cancer tissues of
the proband (III-9) and maternal cousin (III-4) who received
no prior treatment.
DNA samples
Germline DNA was extracted from leukocytes according
to the standard protocols. Frozen tumor samples were
ground to a powder in liquid nitrogen and 30–50 mg of
the sample was used for DNA extraction with the
AllPrep kit (Qiagen). DNA was quantified and its purity
assessed with a NanoDrop ND-1000 spectrophotometer
(Labtech).
Next-generation sequencing
We investigated FH mutations by sequencing the coding
exons and intron flanking regions in both blood and
tumor samples. For targeted next-generation sequen-
cing analysis, the custom primers for FH region were
designed using Ampliseq Designer (Life Technologies).
Library construction and sequencing were carried out
using Ion AmpliSeq Library Kit 2.0, Ion PGM IC 200 kit
and Ion PGM (Life Technologies) according to the
manufacturer's instructions (Additional file 1).
Data analysis
After a sequencing reaction, the raw signal data were
analyzed using Torrent Suite version 4.2.1. The pipeline
includes signaling processing, base calling, quality score
assignment, adapter trimming, mapping to GRCH37/
hg19 reference, detection of mapping quality, and vari-
ant calling. After completion of the primary data ana-
lysis, a list of detected alleles, sequence variant [single-
nucleotide Polymorphisms (SNPs) and the insertion or
the deletion (Indels)] were compiled in a variant call file
format and presented via the web-based user interface.
The results of mapping and variant calling were visual-
ized using Integrative Genome viewer (Broad Institute).
(Additional file 1).
Results
Expression of pAkt and pS6
In six patients, five clear cell RCCs and this case,
receiving preoperative axitinib treatment, similar find-
ings were observed (shrinkage of the tumor, decreased
SUVmax of the tumor, and two thirds tumor tissue
necrosis). For the other patients with cT3bN1 or cT4
clear cell RCC, tumor tissues showed heterogeneous
changes. Some of tumor tissues showed much lower
expression of pAkt (Ser-473), pAkt (Thr-308), and
pS6 than other tissues. On the other hand, in our
current patient with cT3aN1M0, pRCC2, tumor tis-
sues showed high expression of pAkt (Ser-473) and
pAkt (Thr-308), as well as very low expression of pS6
(Fig. 3).
Expression of Nrf2
While much of tumor cells showed diffusely strong
reaction for anti-Nrf2 antibody in the proband (III-9)
and maternal cousin (III-4) (Figs. 4a, 4b), some of viable
tumor cells showed weak staining in the present case
(III-8) (Fig. 4c). Normal kidney and clear cell RCC
tissues showed negative staining (Fig. 4d).
Molecular genetic analysis
The average Ion PGM™ sequencing output per sample
was 150 mega bases with 0.9 million sequencing reads.
Of the 16 amplicons in the FH-gene, 100 % achieved a
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Fig. 3 Western blotting. Western blotting for surgically resected tissues (M: marker, N: normal tissue, T1-3: three different parts of tumor tissues).
In a patient with cT3bN1M1 clear cell renal cell carcinoma (ccRCC-1) who received preoperative axitinib as well as the current patient, tumor tissues
obtained by nephrectomy after axitinib treatment showed heterogeneous changes. Some tumor tissue (T2 and T3) showed much lower expression
of pAkt (Ser-473), pAkt (Thr-308), and pS6 than other tissue (T1). Similarly, in the other patients with cTanyN1Many ccRCCs (ccRCC-2 to −4) treated with
preoperative axitinib, tumor tissues showed heterogeneous pattern. These findings indicate that some parts of the cancer would show a good
response to axitinib but other parts would not. On the other hand, in the present patient with cT3aN1M0, renal cell cancer with papillary type 2
(pRCC2), surgically resected cancer tissues (T1 to T3) showed high expression of pAkt (Ser-473) and pAkt (Thr-308), as well as very low expression
of pS6, indicating that the mTORC2-Akt signaling may be more important for molecular targeting than the mTORC1-S6 pathway in HLRCC-associated
kidney cancer compared with clear cell RCC
Fig. 4 Immunohistochemistry. Immunohistochemical analysis of Nrf2 expression using anti-Nrf2 monoclonal antibody in HLRCC-associated kidney
cancer (a-c) (X 200 magnification. Scale bars showed 200 μm). a, b: Much of cancer cells showed diffuse strong brown staining in a membrane
and cytoplasm for anti-Nrf2 antibody in the proband (III-9) (a) and maternal cousin (III-4) (b) with non-prior therapy. c: Some of viable cancer cell
showed weak reaction in the present case (III-8) with neoadjuvant axitinib therapy. d: Clear cell renal cell carcinoma tissues randomly selected for
this study showed negative staining
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minimum average sequencing depth of 500X and mean
depth were 28,419X-34,591X. In samples, the Ion PGM™
detected SNPs and deletions, details of results are shown
in Table 1. In the blood and resected kidney cancer tis-
sue samples from this patient and the proband (III-9),
common SNPs on exon5 (position; 241,671,938 bp,
C574T, codon p. H235Y) was detected, and new alleles
were detected at intron regions.
Discussion and conclusions
In the present study, next-generation sequencing revealed
that FH mutation and loss of the second allele were
completely identical between blood and tissue samples
from this patient and her sister (III-9) who died of
advanced HLRCC-associated kidney cancer, indicating
that FH-deficient RCC is a unique neoplasm that pro-
gresses directly by FH mutation.
In FH-deficient RCC, oxidative phosphorylation is im-
paired and the cells undergo a shift to aerobic glycolysis,
consistent with the Warburg effect [6, 7]. The conversion
of glucose metabolism from oxidation to glycolysis, the
Warburg effect, is one of the representative strategies for
generation of adenosine triphosphate (ATP) in cancer cells
[27]. Reprogramming of energy metabolism, the conver-
sion of glucose metabolism from oxidation to glycolysis,
the Warburg effect, can now be viewed as one of the “hall-
marks of cancer” [28]. RCC is characterized by impaired
oxidative phosphorylation and a metabolic shift to aerobic
glycolysis, a form of metabolic reprogramming. In
particular, HLRCC-associated kidney cancer cells have lost
the ability to completely cycle through the TCA cycle, due
to the loss of FH enzyme activity, and have effectively lost
the ability to perform oxidative phosphorylation indicating
that these cancers exist in a state of enforced dependence
upon glycolysis and represent a notable example of the
Warburg effect [7]. Thus, HLRCC-associated kidney can-
cer might be a clinical model to study energy metabolism
deregulation, as well as developing new targeted thera-
peutic approaches for TCA cycle enzyme-deficient cancers
[29]. In this HLRCC-associated pRCC2 case, surgically
resected cancer tissue showed high expression of pAkt
(Ser-473) and pAkt (Thr-308), as well as very low ex-
pression of pS6, indicating that we should study the
roles of mTORC2-Akt signaling in HLRCC-associated
kidney cancer from the metabolic point of view in more
patients in the forthcoming study.
On the other hand, FH-deficient RCC is also charac-
terized by increased oxidative stress and elevated levels
of reactive oxygen, thus effective anti-oxidant response
is critical for continued growth [6, 7]. In this study, sub-
sequent immunohistochemical staining for Nrf2 protein
in the HLRCC-associated pRCC2 also showed intense
positive staining (III-9 and −4). At the same time, normal
kidney and clear cell RCC tissues showed negative stain-
ing. Our findings were consistent with those by previous
study [20], indicating that Nrf2 was indeed activated in
these FH-deficient RCC tissues. Thus, FH-deficient RCC
appeared to be linked to increased expression of anti-
Table 1 Allele detection of FH-gene using next-generation DNA sequencer
Sample Chrom Position Ref Variant Allele Call Frequency Quality Type Coverage
Blood chr1 241667244 G T Homozygous 100 3825.7 SNP 399
chr1 241669249 C T Homozygous 100 3797.23 SNP 398
chr1 241671938 G A Heterozygous 63.5 1405.16 SNP 400
chr1 241675240 A – Homozygous 100 2791.44 DEL 387
chr1 241682820 G T Homozygous 100 3806.12 SNP 397
Cancer tissue chr1 241667244 G T Homozygous 100 3853.67 SNP 400
chr1 241669249 C T Homozygous 100 3853.67 SNP 400
chr1 241671938 G A Heterozygous 45 669.28 SNP 400
chr1 241675240 A – Homozygous 100 2733.7 DEL 383
chr1 241682820 G T Homozygous 100 3796.5 SNP 396
Positive Ctrla chr1 241667233 C T Heterozygous 55.5 1058.17 SNP 400
chr1 241667244 G T Heterozygous 51.3 888.08 SNP 398
chr1 241675240 A – Homozygous 100 2622.8 DEL 385
Positive Ctrla : Centre d'Étude du Polymorphisme Human, http://www.cephb.fr/ (for chromosome 2 linkage map and DNA from individual 1347–02)
The average Ion PGM™ sequencing output per sample was 150 mega bases with 0.9 million sequencing reads. Of the 16 amplicons in the FH-gene, 100 %
achieved a minimum average sequencing depth of 500X and mean depth were 28,419X-34,591X. In samples, the Ion PGM™ detected single-nucleotide Polymorphisms
(SNPs) and deletions, details of results are shown in Table 1. In blood sample and cancer tissue sample of the current case, SNPs same as the past report [7], hetero on
FH-gene exon5, was detected, and new alleles were detected at intron regions
SNPs of chr1:241,667,244 bp and chr1:241,675,240 were common between blood, cancer samples and normal human cell (CEPH individuals 1347–02 control DNA,
Lifetechnologies). This result indicates these SNPs have low association with cancer. Other variants were located at intron; such mutations may cause a
proportion of mature messenger RNA with improperly spliced intron sequences. So we will try gene expression profiling, RNA-seq, for these samples
including fusion-gene analysis
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oxidant genes with accompanied by the accumulation of
Nrf2. In this HLRCC-associated pRCC2 case treated with
neoadjuvant axitinib, some of viable cancer cells showed
weak reaction for anti-Nrf2 antibodies compared to the
tumors of the proband (III-9) and maternal cousin (III-4)
who received no prior treatment in which much of cancer
cells showed diffusely strong reaction, indicating that axi-
tinib might suppress the Nrf2 pathway by unknown mech-
anism. Since we do not have preoperative tumor tissues
and stored blood samples, we could not compare the
VEGF levels between before and after administrating axi-
tinib in the present study. However, in addition to pAkt,
pS6, and Nrf2, we should also analyze repeatedly the
VEGF, GLUT1 or HIF using tissue and blood samples in
order to correspond to dynamic change of the tumor and
the general condition which is continuously changed with
time in the future.
From a molecular point of view, insight in the cellular
pathways involved in pathogenesis of HLRCC might lead
to specific options for early diagnosis and targeted ther-
apies. However, since this is only a single case report
about our experience with surgery after axitinib treat-
ment for HLRCC-associated kidney cancer, the results
should be interpreted with consideration of such limita-
tions and definite conclusions cannot be obtained. While
an investigation of the usefulness of axitinib for pre-
operative or neoadjuvant therapy in patients with locally
advanced RCC is now ongoing, availability of axitinib for
adjuvant therapy for RCCs has not yet elucidated.
Although there was no detailed information regarding
histological type of papillary RCC in a previous study
using other kinase inhibitors in papillary RCCs, sunitinib
seems to be more effective than sorafenib [30]. Further-
more, a phase II trial of bevacizumab and erlotinib in
patients with advanced HLRCC-associated pRCC2 as well
as sporadic pRCC2 is currently under way (NCT01130519).
Therefore, it would be great to conduct in vitro studies
using established two HLRCC kidney cancer lines,
UOK262 and UOK268 [29, 31].
It is thought that early diagnosis and provision of
definitive therapy is the best way to reduce the tumor
burden as rapidly as possible. Unlike other hereditary
renal cancers, HLRCC-associated kidney cancer is an
aggressive tumor characterized by metastasis to re-
gional and distant lymph nodes [4]. A recent report
regarding HLRCC-associated kidney cancer recom-
mended that surveillance should preferably be annual
abdominal MRI, and that treatment of renal tumors
should be prompt and generally involve wide surgical
excision with consideration of retroperitoneal lymph
node dissection [5]. Thirteen at-risk individuals from
this HLRCC family had received active surveillance by
annual imaging (abdominal plain CT or ultrasonog-
raphy) at a convenient clinic, however, as shown in
Fig. 2 and Additional file 2: Figure S1, we may overlook
the smaller tumors associated with HLRCC in plain CT
and/or ultrasonography because of low contrast of the
tumors to the normal kidney. Although enhanced CT may
be useful, given the radiation exposure and the adverse
effect of contrast medium, magnetic resonance imaging
(MRI) seems to be suitable for surveillance as recom-
mended [5]. Subsequently, we would ask their attending
physicians at a convenient clinic annual MRI imaging
study every twelve months.
Currently, surgical intervention is the only therapy avail-
able to patients with HLRCCassociated kidney cancers.
The patient underwent radical left nephrectomy and ex-
tended retroperitoneal lymph node dissection (para-aortic
and aorto-caval nodes) after administration of preoperative
axitinib. It is difficult issue how we should follow the
patient. The patient undergoes imaging examination of
chest CT and abdominal MRI at least every three months
and PET scan every six months, and remains well with no
evidence of recurrence at 33 months after the operation.
The patient is receiving axitinib as adjuvant therapy, and
we would like to decrease the dose of axitinib gradually.
Careful patient selection and meticulous surgical technique
are essential in the treatment of patients with HLRCC-
associated kidney cancer, and these points should be further
emphasized in the era of targeted therapy. Collection of
HLRCC-affected family data dedicated to monitoring of
patients will provide information on clinical variability and
outcome measures that will allow clinicians to adjust
diagnostic criteria and management recommendations. It is
our hope that more patients with HLRCC-associated
kidney cancer will be able to achieve a better outcome.
Ethics approval
The patient and many of individuals in this family signed
a consent form that was approved by our institutional
Committee on Human Rights in Research for the analysis
of germline and somatic DNA. On the other hand, some
individuals could not come to our hospital and we could
not get approval for DNA analysis, however, all partici-
pants in this family give approval for the publication of
their clinical and other details in written informed
consent. Furthermore, if the participant has died, then
consent for publication has been sought from the next of
kin of the participant. Thus, we have 'consent to publish'
from all the individuals represented in the family tree in
Fig. 1. This study was conducted in accordance with the
Helsinki Declaration and was approved by the Dokkyo
Medical University Hospital ethical review board.
Consent
Written informed consent was obtained from the patient
and their relatives to sequence their DNA and for the
publication of this case report and any accompanying
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sequence data or images. A copy of the written consent
is available for review by the Editor of this journal.
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Additional file 1: Supplementary Materials and Methods. (DOCX 270 kb)
Additional file 2: Figure S1. Imaging of the left renal tumor. a:
Ultrasonography, b: Enhanced CT, c: MRI T2W1, d: MRI gadolinium.
Lt RCC: left renal cell carcinoma. mLM: metastatic lymph node tumor.
These imaging were at pre-treatment with axitinib. (TIFF 1162 kb)
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